Heart shield: common drug may prevent Chemo-Induced cardiac harm

NCT ID NCT07370506

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether telmisartan, a blood pressure medication, can prevent heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. Researchers will enroll 36 newly diagnosed women and measure changes in heart function and injury markers. If effective, this approach could make chemotherapy safer without reducing its cancer-fighting power.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm doxorubicin induced cardiomyopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tanta University

    Tanta, El Gharbia, 31111, Egypt